Nivolumab vs Opdivo Qvantig
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Non-Small Cell Lung Cancer
Shared mechanism: PD-1 · full Non-Small Cell Lung Cancer pipeline
Nivolumab
Marketed by Bristol-Myers Squibb and partners
NCT01673867 · Phase 3 · completed
This was a large randomized trial comparing nivolumab with active treatment, but it was open-label rather than double-blinded. The prespecified primary endpoint, overall survival, favored nivolumab and was statistically significant; however, the lack of blinding limits the strength of the evidence.
Next expected readout: November 2026 · NCT02955290 (registry estimate)
Reported efficacy
Overall Survival (OS) Time in Months for All Randomized Participants at Primary Endpoint (Randomization until 413 deaths, up to March 2015 (approximately 29 months)): Overall Survival (OS) Time in Months for All Randomized Participants at Primary Endpoint (Randomization until 413 deaths, up to March 2015 (approximately 29 months)): Nivolumab 12.19 Months (95% CI 9.66 to 14.98) vs Docetaxel 9.36 Months (95% CI 8.05 to 10.68) (met)
Result source: NCT01673867
Opdivo Qvantig
Marketed by Bristol-Myers Squibb
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
No aligned efficacy figure on record for this race.
Results for Non-Small Cell Lung Cancer
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | Nivolumab | Opdivo Qvantig |
|---|---|---|
| PFS, median | 12.1 vs 8.1+4 vs placeboNCT0311704922 other results
| —Not reported |
| OS, median | 12.2 vs 9.4vs DocetaxelNCT0167386720 other results
| —Not reported |
| ORR | 61.5% vs 50.5%+11 vs placeboNCT0311704919 other results
| —Not reported |
| Duration of response, median | 11 vs 7+4 vs placeboNCT0311704912 other results
| —Not reported |
PFS, median
- Nivolumab
- 12.1 vs 8.1+4 vs placeboNCT03117049
22 other results
- 5.1 vs 5.5 NCT02477826
- 4.2 vs 5.5 NCT02477826
- 4.9 vs 5.5 NCT02477826
- 5.5 vs 5.5 NCT02477826
- 8.3 vs 5.5 NCT02477826
- 5.8 vs 5.5 NCT02477826
- 16.7 vs 15.6 NCT04026412
- 5.6 vs 5.5 NCT02864251
- 1.5 vs 5.5 NCT02864251
- 4.2 vs 5.9 NCT02041533
- 2.3 vs 4.4 NCT01673867
- 3.5 vs 2.8 NCT01642004
- 16.8 vs 15.7 NCT04026412
- 17.4 vs 15.7 NCT04026412
- 16.8 vs 16.5 NCT04026412
- 17.7 vs 16.5 NCT04026412
- 4.2 vs 5.8 NCT02041533
- 3.7 NCT03090737
- 5.2 NCT02659059
- 10.8 NCT02659059
- 2 NCT05061017
- 2 NCT05061017
- Opdivo Qvantig
- —Not reported
OS, median
- Nivolumab
- 12.2 vs 9.4vs DocetaxelNCT01673867
20 other results
- 9.2 vs 6.0 NCT01642004
- 17.1 vs 14.9 NCT02477826
- 15.7 vs 14.9 NCT02477826
- 17.4 vs 14.9 NCT02477826
- 15.2 vs 14.9 NCT02477826
- 18.3 vs 14.9 NCT02477826
- 21.0 vs 14.9 NCT02477826
- 12.0 vs 9.6 NCT02613507
- 25.4 vs 24.7 NCT03117049
- 12.2 vs 9.5 NCT01673867
- 9.2 vs 6.0 NCT01642004
- 34.6 vs 39.8 NCT04026412
- 39.5 vs 39.8 NCT04026412
- 19.4 vs 15.9 NCT02864251
- 17.1 vs 15.9 NCT02864251
- 14.4 vs 13.2 NCT02041533
- 13.7 vs 13.8 NCT02041533
- 10.6 NCT03090737
- 20.8 NCT02659059
- 19.4 NCT02659059
- Opdivo Qvantig
- —Not reported
ORR
- Nivolumab
- 61.5% vs 50.5%+11 vs placeboNCT03117049
19 other results
- 19.5% vs 12.8% NCT01673867
- 20% vs 8.8% NCT01642004
- 36.4% vs 29.7% NCT02477826
- 27.5% vs 29.7% NCT02477826
- 26.2% vs 29.7% NCT02477826
- 37.9% vs 29.7% NCT02477826
- 52.3% vs 29.7% NCT02477826
- 38.1% vs 29.7% NCT02477826
- 67.6% vs 64.5% NCT04026412
- 72.2% vs 64.5% NCT04026412
- 61.3% vs 57.9% NCT04026412
- 63.1% vs 57.9% NCT04026412
- 26.1% vs 33.5% NCT02041533
- 50.6% vs 43% NCT04623775
- 14.5% NCT01721759
- 17.1% NCT03090737
- 15.4% NCT01721759
- 32.3% NCT02659059
- 47.2% NCT02659059
- Opdivo Qvantig
- —Not reported
Duration of response, median
- Nivolumab
- 11 vs 7+4 vs placeboNCT03117049
12 other results
- 25.8 vs 25.2 NCT04026412
- 31.8 vs 25.2 NCT04026412
- 22.8 vs 27.9 NCT04026412
- 33.2 vs 27.9 NCT04026412
- 17.1 vs 5.5 NCT01673867
- 24.5 vs 8.4 NCT01642004
- 6.7 vs 5.5 NCT02864251
- 50.0 vs 5.5 NCT02864251
- 12 NCT01721759
- 8.4 vs 7.1 NCT04623775
- 35.5 NCT03090737
- 16 NCT01721759
- Opdivo Qvantig
- —Not reported
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
Opdivo Qvantig: no structured comparison results are available for Non-Small Cell Lung Cancer.
Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.
safety
Coverage. Nivolumab: 4 of 4 rows · Opdivo Qvantig: 0 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | Nivolumab |
|---|---|
| Dropout rate | —480 mga NCT01673867 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3 show 43 more results—3 mg/kg NCT01673867 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3 1.7%Nivolumab NCT01673867 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3 —480 mg NCT01642004 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3 —3 mg/kg NCT01642004 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3 3%Nivolumab NCT01642004 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3 1.7%360 mg NCT02998528 · Phase 3 · combination 0.9%3 mg/kg + 1 mg/kg NCT02998528 · Phase 3 · combination 1.3%Part 1-Arm A: Nivolumab NCT02477826 · Phase 3 1.3%Part 1-Arm B: Nivo + Ipi NCT02477826 · Phase 3 · combination 1.1%Part 1-Arm D: Nivo + Ipi NCT02477826 · Phase 3 · combination 2.8%Part 1-Arm G: Nivo + Chemo NCT02477826 · Phase 3 · combination 0.5%Part 2 - Arm H: Nivolumab + Chemot NCT02477826 · Phase 3 · combination 0%Part 3 -Arm J: Nivolumab + Ipilimu NCT02477826 · Phase 3 · combination 66% NCT03444766 · Phase 4 · registry result, not featured evidence 64.1%Arm A:Nivo + CCRT/Nivo + Ipi NCT04026412 · Phase 3 · registry result, not featured evidence · combination 56.9%Arm B: Nivo + CCRT/Nivo NCT04026412 · Phase 3 · registry result, not featured evidence · combination 73.1% NCT03117049 · Phase 3 · registry result, not featured evidence 0.3% NCT02613507 · Phase 3 · registry result, not featured evidence 2.1%Arm A: Nivolumab Plus Platinum-dou NCT02864251 · Phase 3 · registry result, not featured evidence · combination 2.7%Arm B: Nivolumab Plus Ipilimumab NCT02864251 · Phase 3 · registry result, not featured evidence · combination 1.5% NCT02041533 · Phase 3 · registry result, not featured evidence 1.1%480 mg every 4 weeks NCT02713867 · Phase 3 · registry result, not featured evidence 1.6%240 mg every 2 weeks NCT02713867 · Phase 3 · registry result, not featured evidence —Cohort A: Nivolumab Monotherapy (P NCT02066636 · Phase 3 · registry result, not featured evidence · monotherapy —Cohort B: Nivolumab Monotherapy (P NCT02066636 · Phase 3 · registry result, not featured evidence · monotherapy n/a: no completion milestoneNivolumab Monotherapy (Not Randomi NCT02066636 · Phase 3 · registry result, not featured evidence · monotherapy —Nivolumab Monotherapy (Pre-Randomi NCT02066636 · Phase 3 · registry result, not featured evidence · monotherapy 88.2%HBV Participants NCT03195491 · Phase 3 · registry result, not featured evidence 90.6%Non-HBV Participants NCT03195491 · Phase 3 · registry result, not featured evidence 2.5%Part 1: Treatment A NCT04623775 · Phase 2 · registry result, not featured evidence · combination 0%Part 2: Treatment C NCT04623775 · Phase 2 · registry result, not featured evidence · combination 8.7%Arm A - Nivolumab NCT03158129 · Phase 2 · registry result, not featured evidence 23.8%Arm B - Nivolumab + Ipilimumab NCT03158129 · Phase 2 · registry result, not featured evidence · combination 0%Arm C - Nivolumab + Chemotherapy NCT03158129 · Phase 2 · registry result, not featured evidence · combination 9.1%Arm D - Nivolumab + Ipilimumab + C NCT03158129 · Phase 2 · registry result, not featured evidence · combination —Pixatimod (PG545) + Nivolumab + Cy NCT05061017 · Phase 2 · registry result, not featured evidence · combination 0%Pixatimod (PG545) + Nivolumab - Co NCT05061017 · Phase 2 · registry result, not featured evidence · combination 37.9% NCT02350764 · Phase 2 · registry result, not featured evidence —600 mg NCT05005273 · Phase 2 · registry result, not featured evidence · combination n/a: no completion milestone480mg Q4W NCT03090737 · Phase 2 · registry result, not featured evidence 87.2%Nivolumab+Ipilimumab NCT02659059 · Phase 2 · registry result, not featured evidence · combination 88.9%Nivolumab+Ipilimumab+Chemotherapy NCT02659059 · Phase 2 · registry result, not featured evidence · combination n/a: no completion milestone3 mg/kg NCT01721759 · Phase 2 · registry result, not featured evidence |
| Discontinued due to AEs | —480 mga NCT01673867 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3 show 43 more results—3 mg/kg NCT01673867 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3 0.3%Nivolumab NCT01673867 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3 —480 mg NCT01642004 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3 —3 mg/kg NCT01642004 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3 0.7%Nivolumab NCT01642004 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3 0.6%360 mg NCT02998528 · Phase 3 · combination 0%3 mg/kg + 1 mg/kg NCT02998528 · Phase 3 · combination 0.3%Part 1-Arm A: Nivolumab NCT02477826 · Phase 3 0%Part 1-Arm B: Nivo + Ipi NCT02477826 · Phase 3 · combination 0.5%Part 1-Arm D: Nivo + Ipi NCT02477826 · Phase 3 · combination 0%Part 1-Arm G: Nivo + Chemo NCT02477826 · Phase 3 · combination 0.3%Part 2 - Arm H: Nivolumab + Chemot NCT02477826 · Phase 3 · combination 0%Part 3 -Arm J: Nivolumab + Ipilimu NCT02477826 · Phase 3 · combination 6% NCT03444766 · Phase 4 · registry result, not featured evidence —Arm A:Nivo + CCRT/Nivo + Ipi NCT04026412 · Phase 3 · registry result, not featured evidence · combination —Arm B: Nivo + CCRT/Nivo NCT04026412 · Phase 3 · registry result, not featured evidence · combination — NCT03117049 · Phase 3 · registry result, not featured evidence — NCT02613507 · Phase 3 · registry result, not featured evidence 0.7%Arm A: Nivolumab Plus Platinum-dou NCT02864251 · Phase 3 · registry result, not featured evidence · combination 0%Arm B: Nivolumab Plus Ipilimumab NCT02864251 · Phase 3 · registry result, not featured evidence · combination — NCT02041533 · Phase 3 · registry result, not featured evidence —480 mg every 4 weeks NCT02713867 · Phase 3 · registry result, not featured evidence —240 mg every 2 weeks NCT02713867 · Phase 3 · registry result, not featured evidence —Cohort A: Nivolumab Monotherapy (P NCT02066636 · Phase 3 · registry result, not featured evidence · monotherapy —Cohort B: Nivolumab Monotherapy (P NCT02066636 · Phase 3 · registry result, not featured evidence · monotherapy 3.8%Nivolumab Monotherapy (Not Randomi NCT02066636 · Phase 3 · registry result, not featured evidence · monotherapy —Nivolumab Monotherapy (Pre-Randomi NCT02066636 · Phase 3 · registry result, not featured evidence · monotherapy 11.8%HBV Participants NCT03195491 · Phase 3 · registry result, not featured evidence 5%Non-HBV Participants NCT03195491 · Phase 3 · registry result, not featured evidence —Part 1: Treatment A NCT04623775 · Phase 2 · registry result, not featured evidence · combination —Part 2: Treatment C NCT04623775 · Phase 2 · registry result, not featured evidence · combination 0%Arm A - Nivolumab NCT03158129 · Phase 2 · registry result, not featured evidence 4.8%Arm B - Nivolumab + Ipilimumab NCT03158129 · Phase 2 · registry result, not featured evidence · combination 0%Arm C - Nivolumab + Chemotherapy NCT03158129 · Phase 2 · registry result, not featured evidence · combination 0%Arm D - Nivolumab + Ipilimumab + C NCT03158129 · Phase 2 · registry result, not featured evidence · combination —Pixatimod (PG545) + Nivolumab + Cy NCT05061017 · Phase 2 · registry result, not featured evidence · combination —Pixatimod (PG545) + Nivolumab - Co NCT05061017 · Phase 2 · registry result, not featured evidence · combination 13.8% NCT02350764 · Phase 2 · registry result, not featured evidence —600 mg NCT05005273 · Phase 2 · registry result, not featured evidence · combination 5.4%480mg Q4W NCT03090737 · Phase 2 · registry result, not featured evidence 11.1%Nivolumab+Ipilimumab NCT02659059 · Phase 2 · registry result, not featured evidence · combination 11.1%Nivolumab+Ipilimumab+Chemotherapy NCT02659059 · Phase 2 · registry result, not featured evidence · combination 9.4%3 mg/kg NCT01721759 · Phase 2 · registry result, not featured evidence |
| Serious AEs | 33.3%480 mga NCT01673867 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3 show 43 more results59.9%3 mg/kg NCT01673867 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3 —Nivolumab NCT01673867 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3 16.7%480 mg NCT01642004 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3 64.9%3 mg/kg NCT01642004 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3 —Nivolumab NCT01642004 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3 30.1%360 mg NCT02998528 · Phase 3 · combination 27%3 mg/kg + 1 mg/kg NCT02998528 · Phase 3 · combination 61.1%Part 1-Arm A: Nivolumab NCT02477826 · Phase 3 70.3%Part 1-Arm B: Nivo + Ipi NCT02477826 · Phase 3 · combination 69.2%Part 1-Arm D: Nivo + Ipi NCT02477826 · Phase 3 · combination 65.1%Part 1-Arm G: Nivo + Chemo NCT02477826 · Phase 3 · combination 64%Part 2 - Arm H: Nivolumab + Chemot NCT02477826 · Phase 3 · combination 61.9%Part 3 -Arm J: Nivolumab + Ipilimu NCT02477826 · Phase 3 · combination 30% NCT03444766 · Phase 4 · registry result, not featured evidence 63.8%Arm A:Nivo + CCRT/Nivo + Ipi NCT04026412 · Phase 3 · registry result, not featured evidence · combination 56.9%Arm B: Nivo + CCRT/Nivo NCT04026412 · Phase 3 · registry result, not featured evidence · combination 56.4% NCT03117049 · Phase 3 · registry result, not featured evidence 54.3% NCT02613507 · Phase 3 · registry result, not featured evidence 54.6%Arm A: Nivolumab Plus Platinum-dou NCT02864251 · Phase 3 · registry result, not featured evidence · combination 64.8%Arm B: Nivolumab Plus Ipilimumab NCT02864251 · Phase 3 · registry result, not featured evidence · combination 73% NCT02041533 · Phase 3 · registry result, not featured evidence 34.8%480 mg every 4 weeks NCT02713867 · Phase 3 · registry result, not featured evidence 39.4%240 mg every 2 weeks NCT02713867 · Phase 3 · registry result, not featured evidence 44.9%Cohort A: Nivolumab Monotherapy (P NCT02066636 · Phase 3 · registry result, not featured evidence · monotherapy 41.6%Cohort B: Nivolumab Monotherapy (P NCT02066636 · Phase 3 · registry result, not featured evidence · monotherapy —Nivolumab Monotherapy (Not Randomi NCT02066636 · Phase 3 · registry result, not featured evidence · monotherapy 60.9%Nivolumab Monotherapy (Pre-Randomi NCT02066636 · Phase 3 · registry result, not featured evidence · monotherapy 70.6%HBV Participants NCT03195491 · Phase 3 · registry result, not featured evidence 41%Non-HBV Participants NCT03195491 · Phase 3 · registry result, not featured evidence 59.7%Part 1: Treatment A NCT04623775 · Phase 2 · registry result, not featured evidence · combination 65.2%Part 2: Treatment C NCT04623775 · Phase 2 · registry result, not featured evidence · combination 17.4%Arm A - Nivolumab NCT03158129 · Phase 2 · registry result, not featured evidence 14.3%Arm B - Nivolumab + Ipilimumab NCT03158129 · Phase 2 · registry result, not featured evidence · combination 31.8%Arm C - Nivolumab + Chemotherapy NCT03158129 · Phase 2 · registry result, not featured evidence · combination 13.6%Arm D - Nivolumab + Ipilimumab + C NCT03158129 · Phase 2 · registry result, not featured evidence · combination 37.5%Pixatimod (PG545) + Nivolumab + Cy NCT05061017 · Phase 2 · registry result, not featured evidence · combination 20%Pixatimod (PG545) + Nivolumab - Co NCT05061017 · Phase 2 · registry result, not featured evidence · combination 75.9% NCT02350764 · Phase 2 · registry result, not featured evidence 100%600 mg NCT05005273 · Phase 2 · registry result, not featured evidence · combination 43.4%480mg Q4W NCT03090737 · Phase 2 · registry result, not featured evidence 59.4%Nivolumab+Ipilimumab NCT02659059 · Phase 2 · registry result, not featured evidence · combination 72.2%Nivolumab+Ipilimumab+Chemotherapy NCT02659059 · Phase 2 · registry result, not featured evidence · combination 75.2%3 mg/kg NCT01721759 · Phase 2 · registry result, not featured evidence |
| Most frequent reported AEs | 480 mga cough 33.3% arthralgia 20% rash 20% NCT01673867 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3 show 40 more results3 mg/kg fatigue 33.4% decreased appetite 31.7% cough 28.9% NCT01673867 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3 480 mg nausea 33.3% vomiting 33.3% abdominal pain 16.7% NCT01642004 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3 3 mg/kg dyspnoea 35.9% cough 34.4% fatigue 32.1% NCT01642004 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3 anaemia 50% hyponatraemia 37.3% aspartate aminotransferase increased 36.5% NCT02477826 · Phase 3 · combination anaemia 44% nausea 34.8% constipation 29.1% NCT04026412 · Phase 3 · registry result, not featured evidence · combination anaemia 41.5% nausea 32.7% cough 26.1% NCT04026412 · Phase 3 · registry result, not featured evidence · combination constipation 54.9% (placebo 48.7%) alopecia 52.4% (placebo 54.5%) peripheral sensory neuropathy 44.3% (placebo 42.2%) NCT03117049 · Phase 3 · registry result, not featured evidence anaemia 34.7% decreased appetite 31.5% fatigue 31.2% NCT02613507 · Phase 3 · registry result, not featured evidence anaemia 46.8% nausea 44.7% constipation 36.9% NCT02864251 · Phase 3 · registry result, not featured evidence · combination constipation 29.6% pruritus 25.4% diarrhoea 23.9% NCT02864251 · Phase 3 · registry result, not featured evidence · combination fatigue 40.4% decreased appetite 34.1% nausea 32.2% NCT02041533 · Phase 3 · registry result, not featured evidence 480 mg every 4 weeks diarrhoea 16.9% pruritus 16.9% fatigue 15.7% NCT02713867 · Phase 3 · registry result, not featured evidence 240 mg every 2 weeks pruritus 23.3% diarrhoea 22.8% fatigue 22.2% NCT02713867 · Phase 3 · registry result, not featured evidence diarrhoea 28.3% arthralgia 23.6% upper respiratory tract infection 22% NCT02066636 · Phase 3 · registry result, not featured evidence · monotherapy cough 17.6% weight decreased 16% arthralgia 14.4% NCT02066636 · Phase 3 · registry result, not featured evidence · monotherapy fatigue 36.1% dyspnoea 23.7% nausea 23.2% NCT02066636 · Phase 3 · registry result, not featured evidence · monotherapy anaemia 41.2% cough 41.2% hyponatraemia 35.3% NCT03195491 · Phase 3 · registry result, not featured evidence anaemia 40.5% decreased appetite 24.5% cough 22.2% NCT03195491 · Phase 3 · registry result, not featured evidence anaemia 66.2% fatigue 42.9% nausea 42.9% NCT04623775 · Phase 2 · registry result, not featured evidence · combination anaemia 69% nausea 34.8% thrombocytopenia 29.7% NCT04623775 · Phase 2 · registry result, not featured evidence · combination fatigue 34.8% anemia 30.4% rash acneiform 26.1% NCT03158129 · Phase 2 · registry result, not featured evidence rash acneiform 61.9% cough 38.1% fatigue 38.1% NCT03158129 · Phase 2 · registry result, not featured evidence · combination nausea 81.8% fatigue 72.7% anemia 54.5% NCT03158129 · Phase 2 · registry result, not featured evidence · combination anemia 50% diarrhea 40.9% nausea 40.9% NCT03158129 · Phase 2 · registry result, not featured evidence · combination anemia 62.5% fatigue 50% hyponatremia 50% NCT05061017 · Phase 2 · registry result, not featured evidence · combination activated partial thromboplastin time prolonged 80% hypertriglyceridemia 60% hyponatremia 60% NCT05061017 · Phase 2 · registry result, not featured evidence · combination hyperglycemia 100% hypoalbuminemia 93.1% anemia 75.9% NCT02350764 · Phase 2 · registry result, not featured evidence 600 mg blood alkaline phosphatase increased 100% blood lactate dehydrogenase increased 100% bronchitis 100% NCT05005273 · Phase 2 · registry result, not featured evidence · combination 480mg Q4W anaemia 28.7% blood alkaline phosphatase increased 24.8% rash 20.2% NCT03090737 · Phase 2 · registry result, not featured evidence fatigue 55.2% diarrhoea 38.5% nausea 38.2% NCT02659059 · Phase 2 · registry result, not featured evidence · combination fatigue 55.6% pruritus 47.2% nausea 44.4% NCT02659059 · Phase 2 · registry result, not featured evidence · combination 3 mg/kg fatigue 53% decreased appetite 39.3% dyspnoea 38.5% NCT01721759 · Phase 2 · registry result, not featured evidence |
Notes
- aPopulation comparability has not been reviewed for 38 of these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Nivolumab
show 18 more results
show 14 more results
show 5 more results
show 9 more results
show 17 more results
show 2 more results
show 11 more results
show 8 more results
show 1 more result
show 2 more results
+ 41 further endpoints in the CSV export.
Urothelial Carcinoma
Shared mechanism: PD-1 · full Urothelial Carcinoma pipeline
Nivolumab
Marketed by Bristol-Myers Squibb and partners
NCT03036098 · Phase 3 · completed
This was a large randomized trial against standard chemotherapy, but it was open-label. Three of the four primary comparisons were statistically significant, while overall survival in PD-L1 positive patients given nivolumab plus ipilimumab has no posted significance test, so the overall result is mixed.
Next expected readout: December 2026 · NCT06682728 (registry estimate)
Reported efficacy
Overall Survival (OS) in Cisplatin-ineligible Randomized Participants for Primary Study (From the date of randomization to the date of death from any cause, or data cut-off date, whichever occurred first (up to approximately 89 months)); Overall Survival (OS) in Programmed Death-Ligand 1 (PD-L1) Positive (≥ 1%) Randomized Participants by Immunohistochemistry (IHC) for Primary Study (From the date of randomization to the date of death from any cause, or data cut-off date, whichever occurred first (up to approximately 89 months)); Progression-Free Survival (PFS) by Blinded Independent Central Review (BICR) [Using Response Evaluation Criteria in Solid Tumors (RECIST) 1.1] in Cisplatin-eligible Participants for Sub-study (From the date of randomization to the date of first documented disease progression or death due to any cause, whichever occurs first (up to approximately 89 months)); Overall Survival (OS) in Cisplatin-eligible Participants for Sub-study (From the date of randomization to the date of death from any cause, or data cut-off date, whichever occurred first (up to approximately 89 months)): Sub-study (cisplatin-eligible), nivolumab + gemcitabine-cisplatin vs gemcitabine-cisplatin: PFS HR 0.72 (95% CI 0.59 to 0.88), p=0.0018; OS median 21.7 vs 18.9 months, HR 0.78 (95% CI 0.63 to 0.96), p=0.0171. Primary study, nivolumab + ipilimumab vs chemotherapy: OS in PD-L1 >=1% 16.3 vs 14.4 months, primary not met per BMS; OS in cisplatin-ineligible 19.1 vs 13.2 months, HR 0.79 (95% CI 0.64 to 0.97), posted p=0.0032 (CT.gov posted results). (mixed)
Result source: NCT03036098
Opdivo Qvantig
Marketed by Bristol-Myers Squibb
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
No aligned efficacy figure on record for this race.
Results for Urothelial Carcinoma
There are not yet structured results for two selected drugs in this indication. Available results are listed below instead of an empty comparison table.
Opdivo Qvantig: no structured comparison results are available for Urothelial Carcinoma.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Nivolumab
show 1 more result
Available safety results
Nivolumab
| Dropout rate | 0%0.009 mg/kg q3w + 360 mg q3w NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination show 9 more results0%0.006 mg/kg q3w + 240 mg q2w NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination 33.3%0.006 mg/kg q2w + 240 mg q2w NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination 20%0.006 mg/kg q3w + 360 mg q3w NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination 17.2%0.006 mg/kg q3w + 360 mg q3w NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination 0%0.003 mg/kg q2w + 240 mg q2w NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination 0%Part 3 Schedule Finding (Schedule NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination 0%Part 3 Schedule Finding (Schedule NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination 0%Part 3 Schedule Finding (Schedule NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination 10.5%Part 4 Dose Expansion of NKTR-214 NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination |
|---|---|
| Discontinued due to AEs | —0.009 mg/kg q3w + 360 mg q3w NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination show 9 more results—0.006 mg/kg q3w + 240 mg q2w NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination —0.006 mg/kg q2w + 240 mg q2w NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination —0.006 mg/kg q3w + 360 mg q3w NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination —0.006 mg/kg q3w + 360 mg q3w NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination —0.003 mg/kg q2w + 240 mg q2w NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination —Part 3 Schedule Finding (Schedule NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination —Part 3 Schedule Finding (Schedule NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination —Part 3 Schedule Finding (Schedule NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination —Part 4 Dose Expansion of NKTR-214 NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination |
| Serious AEs | 66.7%0.009 mg/kg q3w + 360 mg q3w NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination show 9 more results50%0.006 mg/kg q3w + 240 mg q2w NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination 0%0.006 mg/kg q2w + 240 mg q2w NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination 36%0.006 mg/kg q3w + 360 mg q3w NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination 44.7%0.006 mg/kg q3w + 360 mg q3w NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination 33.3%0.003 mg/kg q2w + 240 mg q2w NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination 60%Part 3 Schedule Finding (Schedule NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination 62.5%Part 3 Schedule Finding (Schedule NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination 33.3%Part 3 Schedule Finding (Schedule NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination 42.1%Part 4 Dose Expansion of NKTR-214 NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination |
| Most frequent reported AEs | 0.009 mg/kg q3w + 360 mg q3w pyrexia 100% rash 100% chills 66.7% NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination show 9 more results0.006 mg/kg q3w + 240 mg q2w arthralgia 100% fatigue 100% headache 100% NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination 0.006 mg/kg q2w + 240 mg q2w chills 100% pyrexia 100% back pain 66.7% NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination 0.006 mg/kg q3w + 360 mg q3w fatigue 76% chills 64% cough 60% NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination 0.006 mg/kg q3w + 360 mg q3w fatigue 50.6% pyrexia 47.9% nausea 40.1% NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination 0.003 mg/kg q2w + 240 mg q2w chills 100% nasal congestion 100% arthralgia 66.7% NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination fatigue 90% diarrhoea 80% nausea 80% NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination diarrhoea 75% influenza like illness 75% pruritus 75% NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination decreased appetite 100% fatigue 100% influenza like illness 100% NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination fatigue 78.9% influenza like illness 68.4% nausea 57.9% NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination |
Hepatocellular Carcinoma
Shared mechanism: PD-1 · full Hepatocellular Carcinoma pipeline
Nivolumab
Marketed by Bristol-Myers Squibb and partners
NCT04039607 · Phase 3 · completed
This was a large randomized phase 3 trial against an active comparator, and its primary endpoint, overall survival, was met with statistical significance. Patients and doctors knew which treatment was given, but survival is an objective outcome that this knowledge cannot change; an open-label design still keeps the evidence below the top level.
Next expected readout: December 2026 · NCT07176650 (registry estimate)
No aligned efficacy figure on record for this race.
Opdivo Qvantig
Marketed by Bristol-Myers Squibb
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
No aligned efficacy figure on record for this race.
Results for Hepatocellular Carcinoma
There are not yet structured results for two selected drugs in this indication. Available results are listed below instead of an empty comparison table.
Opdivo Qvantig: no structured comparison results are available for Hepatocellular Carcinoma.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Nivolumab
show 1 more result
show 1 more result
show 1 more result
Available safety results
Nivolumab
| Dropout rate | 0%Galunisertib + Nivolumab (Cohort 1 NCT02423343 · Phase 1/2 · registry result, not featured evidence · combination show 5 more results20%Galunisertib + Nivolumab (Cohort 2 NCT02423343 · Phase 1/2 · registry result, not featured evidence · combination 0%Galunisertib + Nivolumab (Cohort 3 NCT02423343 · Phase 1/2 · registry result, not featured evidence · combination 0%Galunisertib + Nivolumab (Cohort 4 NCT02423343 · Phase 1/2 · registry result, not featured evidence · combination —Galunisertib + Nivolumab (HCC) Pha NCT02423343 · Phase 1/2 · registry result, not featured evidence · combination —Galunisertib + Nivolumab (NSCLC) P NCT02423343 · Phase 1/2 · registry result, not featured evidence · combination |
|---|---|
| Discontinued due to AEs | 0%Galunisertib + Nivolumab (Cohort 1 NCT02423343 · Phase 1/2 · registry result, not featured evidence · combination show 5 more results0%Galunisertib + Nivolumab (Cohort 2 NCT02423343 · Phase 1/2 · registry result, not featured evidence · combination 0%Galunisertib + Nivolumab (Cohort 3 NCT02423343 · Phase 1/2 · registry result, not featured evidence · combination 0%Galunisertib + Nivolumab (Cohort 4 NCT02423343 · Phase 1/2 · registry result, not featured evidence · combination —Galunisertib + Nivolumab (HCC) Pha NCT02423343 · Phase 1/2 · registry result, not featured evidence · combination —Galunisertib + Nivolumab (NSCLC) P NCT02423343 · Phase 1/2 · registry result, not featured evidence · combination |
| Serious AEs | 33.3%Galunisertib + Nivolumab (Cohort 1 NCT02423343 · Phase 1/2 · registry result, not featured evidence · combination show 5 more results40%Galunisertib + Nivolumab (Cohort 2 NCT02423343 · Phase 1/2 · registry result, not featured evidence · combination 33.3%Galunisertib + Nivolumab (Cohort 3 NCT02423343 · Phase 1/2 · registry result, not featured evidence · combination 50%Galunisertib + Nivolumab (Cohort 4 NCT02423343 · Phase 1/2 · registry result, not featured evidence · combination 0%Galunisertib + Nivolumab (HCC) Pha NCT02423343 · Phase 1/2 · registry result, not featured evidence · combination 52%Galunisertib + Nivolumab (NSCLC) P NCT02423343 · Phase 1/2 · registry result, not featured evidence · combination |
| Most frequent reported AEs | vomiting 66.7% dehydration 33.3% depression 33.3% NCT02423343 · Phase 1/2 · registry result, not featured evidence · combination show 5 more resultsdiarrhoea 40% pulmonary embolism 40% abdominal pain 20% NCT02423343 · Phase 1/2 · registry result, not featured evidence · combination dyspnoea 33.3% headache 33.3% hyperglycaemia 33.3% NCT02423343 · Phase 1/2 · registry result, not featured evidence · combination amylase increased 75% aspartate aminotransferase increased 50% blood alkaline phosphatase increased 50% NCT02423343 · Phase 1/2 · registry result, not featured evidence · combination gingivitis 100% rhinorrhoea 100% abdominal distension 0% NCT02423343 · Phase 1/2 · registry result, not featured evidence · combination pruritus 36% decreased appetite 28% diarrhoea 28% NCT02423343 · Phase 1/2 · registry result, not featured evidence · combination |
Gastric Cancer
Shared mechanism: PD-1 · full Gastric Cancer pipeline
Nivolumab
Marketed by Bristol-Myers Squibb and partners
NCT02872116 · Phase 3 · completed
The trial randomized 2,031 participants to nivolumab plus chemotherapy or active chemotherapy control, but treatment assignment was open-label rather than double-blinded. Its clinical primary endpoints were met, with statistically significant improvements in both overall survival and progression-free survival; however, the available record does not report a power calculation, so the evidence is graded moderate.
Next expected readout: December 2026 · NCT04900818 (registry estimate)
No aligned efficacy figure on record for this race.
Opdivo Qvantig
Marketed by Bristol-Myers Squibb
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
No aligned efficacy figure on record for this race.
Results for Gastric Cancer
There are not yet structured results for two selected drugs in this indication. Available results are listed below instead of an empty comparison table.
Opdivo Qvantig: no structured comparison results are available for Gastric Cancer.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Nivolumab
show 1 more result
Available safety results
Nivolumab
| Dropout rate | 0%0.009 mg/kg q3w + 360 mg q3w NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination show 9 more results0%0.006 mg/kg q3w + 240 mg q2w NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination 33.3%0.006 mg/kg q2w + 240 mg q2w NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination 20%0.006 mg/kg q3w + 360 mg q3w NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination 17.2%0.006 mg/kg q3w + 360 mg q3w NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination 0%0.003 mg/kg q2w + 240 mg q2w NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination 0%Part 3 Schedule Finding (Schedule NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination 0%Part 3 Schedule Finding (Schedule NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination 0%Part 3 Schedule Finding (Schedule NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination 10.5%Part 4 Dose Expansion of NKTR-214 NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination |
|---|---|
| Discontinued due to AEs | —0.009 mg/kg q3w + 360 mg q3w NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination show 9 more results—0.006 mg/kg q3w + 240 mg q2w NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination —0.006 mg/kg q2w + 240 mg q2w NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination —0.006 mg/kg q3w + 360 mg q3w NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination —0.006 mg/kg q3w + 360 mg q3w NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination —0.003 mg/kg q2w + 240 mg q2w NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination —Part 3 Schedule Finding (Schedule NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination —Part 3 Schedule Finding (Schedule NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination —Part 3 Schedule Finding (Schedule NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination —Part 4 Dose Expansion of NKTR-214 NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination |
| Serious AEs | 66.7%0.009 mg/kg q3w + 360 mg q3w NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination show 9 more results50%0.006 mg/kg q3w + 240 mg q2w NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination 0%0.006 mg/kg q2w + 240 mg q2w NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination 36%0.006 mg/kg q3w + 360 mg q3w NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination 44.7%0.006 mg/kg q3w + 360 mg q3w NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination 33.3%0.003 mg/kg q2w + 240 mg q2w NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination 60%Part 3 Schedule Finding (Schedule NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination 62.5%Part 3 Schedule Finding (Schedule NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination 33.3%Part 3 Schedule Finding (Schedule NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination 42.1%Part 4 Dose Expansion of NKTR-214 NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination |
| Most frequent reported AEs | 0.009 mg/kg q3w + 360 mg q3w pyrexia 100% rash 100% chills 66.7% NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination show 9 more results0.006 mg/kg q3w + 240 mg q2w arthralgia 100% fatigue 100% headache 100% NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination 0.006 mg/kg q2w + 240 mg q2w chills 100% pyrexia 100% back pain 66.7% NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination 0.006 mg/kg q3w + 360 mg q3w fatigue 76% chills 64% cough 60% NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination 0.006 mg/kg q3w + 360 mg q3w fatigue 50.6% pyrexia 47.9% nausea 40.1% NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination 0.003 mg/kg q2w + 240 mg q2w chills 100% nasal congestion 100% arthralgia 66.7% NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination fatigue 90% diarrhoea 80% nausea 80% NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination diarrhoea 75% influenza like illness 75% pruritus 75% NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination decreased appetite 100% fatigue 100% influenza like illness 100% NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination fatigue 78.9% influenza like illness 68.4% nausea 57.9% NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination |
Melanoma
Shared mechanism: PD-1 · full Melanoma pipeline
Nivolumab
Marketed by Bristol-Myers Squibb and partners
NCT01721746 · Phase 3 · completed
This was a large randomized trial against chemotherapy, but it was open-label. Overall survival, an objective outcome, was not significantly better with nivolumab, although more patients had a tumour response.
Next expected readout: November 2026 · NCT06712927 (registry estimate)
Reported efficacy
Recurrence-free Survival (RFS) (up to 36 months): Recurrence-free Survival (RFS) (up to 36 months): Nivolumab 3 mg/kg 52.37 Months | Ipilimumab 10 mg/kg 24.08 Months (95% CI 16.56 to 35.09) (met)
Result source: NCT02388906
Opdivo Qvantig
Marketed by Bristol-Myers Squibb
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
No aligned efficacy figure on record for this race.
Results for Melanoma
There are not yet structured results for two selected drugs in this indication. Available results are listed below instead of an empty comparison table.
Opdivo Qvantig: no structured comparison results are available for Melanoma.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Nivolumab
show 1 more result
show 1 more result
show 1 more result
show 1 more result
show 1 more result
show 8 more results
show 1 more result
show 1 more result
show 1 more result
show 2 more results
show 2 more results
show 14 more results
+ 7 further endpoints in the CSV export.
Available safety results
Nivolumab
| Dropout rate | —Pixatimod (PG545) + Nivolumab + Cy NCT05061017 · Phase 2 · registry result, not featured evidence · combination show 66 more results0%Pixatimod (PG545) + Nivolumab - Co NCT05061017 · Phase 2 · registry result, not featured evidence · combination 100%40 mg NCT02718066 · Phase 1/2 · registry result, not featured evidence · combination 100%30 mg NCT02718066 · Phase 1/2 · registry result, not featured evidence · combination 97.5%30 mg NCT02718066 · Phase 1/2 · registry result, not featured evidence · combination 100%20 mg NCT02718066 · Phase 1/2 · registry result, not featured evidence · combination 0%0.009 mg/kg q3w + 360 mg q3w NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination 0%0.006 mg/kg q3w + 240 mg q2w NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination 33.3%0.006 mg/kg q2w + 240 mg q2w NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination 20%0.006 mg/kg q3w + 360 mg q3w NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination 17.2%0.006 mg/kg q3w + 360 mg q3w NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination 0%0.003 mg/kg q2w + 240 mg q2w NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination 0%Part 3 Schedule Finding (Schedule NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination 0%Part 3 Schedule Finding (Schedule NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination 0%Part 3 Schedule Finding (Schedule NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination 10.5%Part 4 Dose Expansion of NKTR-214 NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination —400 mg NCT02658890 · Phase 1/2 · registry result, not featured evidence —BMS-986205 400 mg + nivolumab 240 mg NCT02658890 · Phase 1/2 · registry result, not featured evidence · combination 0%BMS-986205 400 mg + nivolumab 240 mg NCT02658890 · Phase 1/2 · registry result, not featured evidence · combination 0%BMS-986205 200 mg + nivolumab 240 mg NCT02658890 · Phase 1/2 · registry result, not featured evidence · combination 0%BMS-986205 200 mg NCT02658890 · Phase 1/2 · registry result, not featured evidence · combination 0%BMS-986205 200 mg NCT02658890 · Phase 1/2 · registry result, not featured evidence · combination 0%BMS-986205 200 mg NCT02658890 · Phase 1/2 · registry result, not featured evidence · combination 0%BMS-986205 100 mg + nivolumab 240 mg NCT02658890 · Phase 1/2 · registry result, not featured evidence · combination 0%BMS-986205 100 mg NCT02658890 · Phase 1/2 · registry result, not featured evidence · combination 0%BMS-986205 100 mg NCT02658890 · Phase 1/2 · registry result, not featured evidence · combination 0%BMS-986205 100 mg NCT02658890 · Phase 1/2 · registry result, not featured evidence · combination —50 mg NCT02658890 · Phase 1/2 · registry result, not featured evidence 0%BMS-986205 50 mg + nivolumab 240 mg NCT02658890 · Phase 1/2 · registry result, not featured evidence · combination 0%50 mg NCT02658890 · Phase 1/2 · registry result, not featured evidence 0%BMS-986205 25 mg + nivolumab 240 mg NCT02658890 · Phase 1/2 · registry result, not featured evidence · combination 0%Food Effect/ Relative BA (FE BA) S NCT02658890 · Phase 1/2 · registry result, not featured evidence 0%Part 2: Exp ML Anti-PDL1+CTLA4 NCT02658890 · Phase 1/2 · registry result, not featured evidence · combination 0%Part 2: Exp ML BRAF-MT- NIVO NCT02658890 · Phase 1/2 · registry result, not featured evidence · combination —0.3 mg/kg + Nivolumab NCT03123783 · Phase 1/2 · registry result, not featured evidence · combination —0.1 mg/kg + Nivolumab NCT03123783 · Phase 1/2 · registry result, not featured evidence · combination —0.03 mg/kg + Nivolumab NCT03123783 · Phase 1/2 · registry result, not featured evidence · combination —Cohort 1(Arm)/ inNSCLC (Phase 2) - NCT03123783 · Phase 1/2 · registry result, not featured evidence · combination —Cohort 2(Arm)/ PD1-MM (Phase 2) - NCT03123783 · Phase 1/2 · registry result, not featured evidence · combination —Cohort 3A(Arm)/ PD1-NSCLC (Phase 2 NCT03123783 · Phase 1/2 · registry result, not featured evidence · combination —Cohort 3B(Arm)/ PD1-NSCLC (Phase 2 NCT03123783 · Phase 1/2 · registry result, not featured evidence · combination 100%3.2/4 mg NCT02009449 · Phase 1 · registry result, not featured evidence 100%3.2/4 mg NCT02009449 · Phase 1 · registry result, not featured evidence · combination 99.1%1.6/2 mg NCT02009449 · Phase 1 · registry result, not featured evidence 100%1.6/2 mg NCT02009449 · Phase 1 · registry result, not featured evidence · combination 96.5%1.6/2 mg NCT02009449 · Phase 1 · registry result, not featured evidence · combination 100%0.8/1 mg NCT02009449 · Phase 1 · registry result, not featured evidence 100%0.8/1 mg NCT02009449 · Phase 1 · registry result, not featured evidence · combination 100%0.8/1 mg NCT02009449 · Phase 1 · registry result, not featured evidence · combination 100%0.8/ 1 mg NCT02009449 · Phase 1 · registry result, not featured evidence · combination —0.8/1 mg NCT02009449 · Phase 1 · registry result, not featured evidence · combination 100%0.8/1 mg NCT02009449 · Phase 1 · registry result, not featured evidence · combination 85.7%0.8/1 mg NCT02009449 · Phase 1 · registry result, not featured evidence · combination 100%0.8/1 mg NCT02009449 · Phase 1 · registry result, not featured evidence · combination 100%0.8/1 mg NCT02009449 · Phase 1 · registry result, not featured evidence · combination 100%0.4/0.5 mg NCT02009449 · Phase 1 · registry result, not featured evidence 100%0.4/0.5 mg NCT02009449 · Phase 1 · registry result, not featured evidence · combination 100%0.4/ 0.5 mg NCT02009449 · Phase 1 · registry result, not featured evidence · combination —0.4/0.5 mg NCT02009449 · Phase 1 · registry result, not featured evidence · combination 100%0.4/0.5 mg NCT02009449 · Phase 1 · registry result, not featured evidence · combination 100%0.2/0.25 mg NCT02009449 · Phase 1 · registry result, not featured evidence 100%0.2/0.25 mg NCT02009449 · Phase 1 · registry result, not featured evidence · combination 100%0.08/0.1 mg NCT02009449 · Phase 1 · registry result, not featured evidence 0%280 mg PO BID NCT03229278 · Phase 1 · registry result, not featured evidence · combination 0%140 mg / 280 mg NCT03229278 · Phase 1 · registry result, not featured evidence · combination 0%140 mg PO BID NCT03229278 · Phase 1 · registry result, not featured evidence · combination 0%140 mg PO daily NCT03229278 · Phase 1 · registry result, not featured evidence · combination |
|---|---|
| Discontinued due to AEs | —Pixatimod (PG545) + Nivolumab + Cy NCT05061017 · Phase 2 · registry result, not featured evidence · combination show 66 more results—Pixatimod (PG545) + Nivolumab - Co NCT05061017 · Phase 2 · registry result, not featured evidence · combination —40 mg NCT02718066 · Phase 1/2 · registry result, not featured evidence · combination —30 mg NCT02718066 · Phase 1/2 · registry result, not featured evidence · combination —30 mg NCT02718066 · Phase 1/2 · registry result, not featured evidence · combination —20 mg NCT02718066 · Phase 1/2 · registry result, not featured evidence · combination —0.009 mg/kg q3w + 360 mg q3w NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination —0.006 mg/kg q3w + 240 mg q2w NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination —0.006 mg/kg q2w + 240 mg q2w NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination —0.006 mg/kg q3w + 360 mg q3w NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination —0.006 mg/kg q3w + 360 mg q3w NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination —0.003 mg/kg q2w + 240 mg q2w NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination —Part 3 Schedule Finding (Schedule NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination —Part 3 Schedule Finding (Schedule NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination —Part 3 Schedule Finding (Schedule NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination —Part 4 Dose Expansion of NKTR-214 NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination —400 mg NCT02658890 · Phase 1/2 · registry result, not featured evidence —BMS-986205 400 mg + nivolumab 240 mg NCT02658890 · Phase 1/2 · registry result, not featured evidence · combination —BMS-986205 400 mg + nivolumab 240 mg NCT02658890 · Phase 1/2 · registry result, not featured evidence · combination —BMS-986205 200 mg + nivolumab 240 mg NCT02658890 · Phase 1/2 · registry result, not featured evidence · combination —BMS-986205 200 mg NCT02658890 · Phase 1/2 · registry result, not featured evidence · combination —BMS-986205 200 mg NCT02658890 · Phase 1/2 · registry result, not featured evidence · combination —BMS-986205 200 mg NCT02658890 · Phase 1/2 · registry result, not featured evidence · combination —BMS-986205 100 mg + nivolumab 240 mg NCT02658890 · Phase 1/2 · registry result, not featured evidence · combination —BMS-986205 100 mg NCT02658890 · Phase 1/2 · registry result, not featured evidence · combination —BMS-986205 100 mg NCT02658890 · Phase 1/2 · registry result, not featured evidence · combination —BMS-986205 100 mg NCT02658890 · Phase 1/2 · registry result, not featured evidence · combination —50 mg NCT02658890 · Phase 1/2 · registry result, not featured evidence —BMS-986205 50 mg + nivolumab 240 mg NCT02658890 · Phase 1/2 · registry result, not featured evidence · combination —50 mg NCT02658890 · Phase 1/2 · registry result, not featured evidence —BMS-986205 25 mg + nivolumab 240 mg NCT02658890 · Phase 1/2 · registry result, not featured evidence · combination —Food Effect/ Relative BA (FE BA) S NCT02658890 · Phase 1/2 · registry result, not featured evidence —Part 2: Exp ML Anti-PDL1+CTLA4 NCT02658890 · Phase 1/2 · registry result, not featured evidence · combination —Part 2: Exp ML BRAF-MT- NIVO NCT02658890 · Phase 1/2 · registry result, not featured evidence · combination —0.3 mg/kg + Nivolumab NCT03123783 · Phase 1/2 · registry result, not featured evidence · combination —0.1 mg/kg + Nivolumab NCT03123783 · Phase 1/2 · registry result, not featured evidence · combination —0.03 mg/kg + Nivolumab NCT03123783 · Phase 1/2 · registry result, not featured evidence · combination —Cohort 1(Arm)/ inNSCLC (Phase 2) - NCT03123783 · Phase 1/2 · registry result, not featured evidence · combination —Cohort 2(Arm)/ PD1-MM (Phase 2) - NCT03123783 · Phase 1/2 · registry result, not featured evidence · combination —Cohort 3A(Arm)/ PD1-NSCLC (Phase 2 NCT03123783 · Phase 1/2 · registry result, not featured evidence · combination —Cohort 3B(Arm)/ PD1-NSCLC (Phase 2 NCT03123783 · Phase 1/2 · registry result, not featured evidence · combination —3.2/4 mg NCT02009449 · Phase 1 · registry result, not featured evidence —3.2/4 mg NCT02009449 · Phase 1 · registry result, not featured evidence · combination —1.6/2 mg NCT02009449 · Phase 1 · registry result, not featured evidence —1.6/2 mg NCT02009449 · Phase 1 · registry result, not featured evidence · combination —1.6/2 mg NCT02009449 · Phase 1 · registry result, not featured evidence · combination —0.8/1 mg NCT02009449 · Phase 1 · registry result, not featured evidence —0.8/1 mg NCT02009449 · Phase 1 · registry result, not featured evidence · combination —0.8/1 mg NCT02009449 · Phase 1 · registry result, not featured evidence · combination —0.8/ 1 mg NCT02009449 · Phase 1 · registry result, not featured evidence · combination —0.8/1 mg NCT02009449 · Phase 1 · registry result, not featured evidence · combination —0.8/1 mg NCT02009449 · Phase 1 · registry result, not featured evidence · combination —0.8/1 mg NCT02009449 · Phase 1 · registry result, not featured evidence · combination —0.8/1 mg NCT02009449 · Phase 1 · registry result, not featured evidence · combination —0.8/1 mg NCT02009449 · Phase 1 · registry result, not featured evidence · combination —0.4/0.5 mg NCT02009449 · Phase 1 · registry result, not featured evidence —0.4/0.5 mg NCT02009449 · Phase 1 · registry result, not featured evidence · combination —0.4/ 0.5 mg NCT02009449 · Phase 1 · registry result, not featured evidence · combination —0.4/0.5 mg NCT02009449 · Phase 1 · registry result, not featured evidence · combination —0.4/0.5 mg NCT02009449 · Phase 1 · registry result, not featured evidence · combination —0.2/0.25 mg NCT02009449 · Phase 1 · registry result, not featured evidence —0.2/0.25 mg NCT02009449 · Phase 1 · registry result, not featured evidence · combination —0.08/0.1 mg NCT02009449 · Phase 1 · registry result, not featured evidence —280 mg PO BID NCT03229278 · Phase 1 · registry result, not featured evidence · combination —140 mg / 280 mg NCT03229278 · Phase 1 · registry result, not featured evidence · combination —140 mg PO BID NCT03229278 · Phase 1 · registry result, not featured evidence · combination —140 mg PO daily NCT03229278 · Phase 1 · registry result, not featured evidence · combination |
| Serious AEs | 37.5%Pixatimod (PG545) + Nivolumab + Cy NCT05061017 · Phase 2 · registry result, not featured evidence · combination show 66 more results20%Pixatimod (PG545) + Nivolumab - Co NCT05061017 · Phase 2 · registry result, not featured evidence · combination 57.1%40 mg NCT02718066 · Phase 1/2 · registry result, not featured evidence · combination 85.7%30 mg NCT02718066 · Phase 1/2 · registry result, not featured evidence · combination 49.4%30 mg NCT02718066 · Phase 1/2 · registry result, not featured evidence · combination 33.3%20 mg NCT02718066 · Phase 1/2 · registry result, not featured evidence · combination 66.7%0.009 mg/kg q3w + 360 mg q3w NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination 50%0.006 mg/kg q3w + 240 mg q2w NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination 0%0.006 mg/kg q2w + 240 mg q2w NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination 36%0.006 mg/kg q3w + 360 mg q3w NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination 44.7%0.006 mg/kg q3w + 360 mg q3w NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination 33.3%0.003 mg/kg q2w + 240 mg q2w NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination 60%Part 3 Schedule Finding (Schedule NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination 62.5%Part 3 Schedule Finding (Schedule NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination 33.3%Part 3 Schedule Finding (Schedule NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination 42.1%Part 4 Dose Expansion of NKTR-214 NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination 100%400 mg NCT02658890 · Phase 1/2 · registry result, not featured evidence 83.3%BMS-986205 400 mg + nivolumab 240 mg NCT02658890 · Phase 1/2 · registry result, not featured evidence · combination —BMS-986205 400 mg + nivolumab 240 mg NCT02658890 · Phase 1/2 · registry result, not featured evidence · combination 66.7%BMS-986205 200 mg + nivolumab 240 mg NCT02658890 · Phase 1/2 · registry result, not featured evidence · combination 68.8%BMS-986205 200 mg NCT02658890 · Phase 1/2 · registry result, not featured evidence · combination 82.4%BMS-986205 200 mg NCT02658890 · Phase 1/2 · registry result, not featured evidence · combination 64.3%BMS-986205 200 mg NCT02658890 · Phase 1/2 · registry result, not featured evidence · combination 66.7%BMS-986205 100 mg + nivolumab 240 mg NCT02658890 · Phase 1/2 · registry result, not featured evidence · combination 85.7%BMS-986205 100 mg NCT02658890 · Phase 1/2 · registry result, not featured evidence · combination 83.3%BMS-986205 100 mg NCT02658890 · Phase 1/2 · registry result, not featured evidence · combination 80%BMS-986205 100 mg NCT02658890 · Phase 1/2 · registry result, not featured evidence · combination 100%50 mg NCT02658890 · Phase 1/2 · registry result, not featured evidence 60%BMS-986205 50 mg + nivolumab 240 mg NCT02658890 · Phase 1/2 · registry result, not featured evidence · combination 0%50 mg NCT02658890 · Phase 1/2 · registry result, not featured evidence 71.4%BMS-986205 25 mg + nivolumab 240 mg NCT02658890 · Phase 1/2 · registry result, not featured evidence · combination 50%Food Effect/ Relative BA (FE BA) S NCT02658890 · Phase 1/2 · registry result, not featured evidence 58.8%Part 2: Exp ML Anti-PDL1+CTLA4 NCT02658890 · Phase 1/2 · registry result, not featured evidence · combination 16.7%Part 2: Exp ML BRAF-MT- NIVO NCT02658890 · Phase 1/2 · registry result, not featured evidence · combination 0%0.3 mg/kg + Nivolumab NCT03123783 · Phase 1/2 · registry result, not featured evidence · combination 33.3%0.1 mg/kg + Nivolumab NCT03123783 · Phase 1/2 · registry result, not featured evidence · combination 33.3%0.03 mg/kg + Nivolumab NCT03123783 · Phase 1/2 · registry result, not featured evidence · combination 47.2%Cohort 1(Arm)/ inNSCLC (Phase 2) - NCT03123783 · Phase 1/2 · registry result, not featured evidence · combination 15.8%Cohort 2(Arm)/ PD1-MM (Phase 2) - NCT03123783 · Phase 1/2 · registry result, not featured evidence · combination 42.9%Cohort 3A(Arm)/ PD1-NSCLC (Phase 2 NCT03123783 · Phase 1/2 · registry result, not featured evidence · combination 46.4%Cohort 3B(Arm)/ PD1-NSCLC (Phase 2 NCT03123783 · Phase 1/2 · registry result, not featured evidence · combination 40%3.2/4 mg NCT02009449 · Phase 1 · registry result, not featured evidence 60%3.2/4 mg NCT02009449 · Phase 1 · registry result, not featured evidence · combination 51.3%1.6/2 mg NCT02009449 · Phase 1 · registry result, not featured evidence 47.1%1.6/2 mg NCT02009449 · Phase 1 · registry result, not featured evidence · combination 56.1%1.6/2 mg NCT02009449 · Phase 1 · registry result, not featured evidence · combination 33.3%0.8/1 mg NCT02009449 · Phase 1 · registry result, not featured evidence 55.6%0.8/1 mg NCT02009449 · Phase 1 · registry result, not featured evidence · combination 66.7%0.8/1 mg NCT02009449 · Phase 1 · registry result, not featured evidence · combination —0.8/ 1 mg NCT02009449 · Phase 1 · registry result, not featured evidence · combination 66.7%0.8/1 mg NCT02009449 · Phase 1 · registry result, not featured evidence · combination 16.7%0.8/1 mg NCT02009449 · Phase 1 · registry result, not featured evidence · combination 57.1%0.8/1 mg NCT02009449 · Phase 1 · registry result, not featured evidence · combination 100%0.8/1 mg NCT02009449 · Phase 1 · registry result, not featured evidence · combination 20%0.8/1 mg NCT02009449 · Phase 1 · registry result, not featured evidence · combination 33.3%0.4/0.5 mg NCT02009449 · Phase 1 · registry result, not featured evidence 33.3%0.4/0.5 mg NCT02009449 · Phase 1 · registry result, not featured evidence · combination —0.4/ 0.5 mg NCT02009449 · Phase 1 · registry result, not featured evidence · combination 33.3%0.4/0.5 mg NCT02009449 · Phase 1 · registry result, not featured evidence · combination 40%0.4/0.5 mg NCT02009449 · Phase 1 · registry result, not featured evidence · combination 33.3%0.2/0.25 mg NCT02009449 · Phase 1 · registry result, not featured evidence 0%0.2/0.25 mg NCT02009449 · Phase 1 · registry result, not featured evidence · combination 75%0.08/0.1 mg NCT02009449 · Phase 1 · registry result, not featured evidence 14.3%280 mg PO BID NCT03229278 · Phase 1 · registry result, not featured evidence · combination 0%140 mg / 280 mg NCT03229278 · Phase 1 · registry result, not featured evidence · combination 66.7%140 mg PO BID NCT03229278 · Phase 1 · registry result, not featured evidence · combination 100%140 mg PO daily NCT03229278 · Phase 1 · registry result, not featured evidence · combination |
| Most frequent reported AEs | anemia 62.5% fatigue 50% hyponatremia 50% NCT05061017 · Phase 2 · registry result, not featured evidence · combination show 63 more resultsactivated partial thromboplastin time prolonged 80% hypertriglyceridemia 60% hyponatremia 60% NCT05061017 · Phase 2 · registry result, not featured evidence · combination 40 mg anaemia 57.1% decreased appetite 57.1% contusion 42.9% NCT02718066 · Phase 1/2 · registry result, not featured evidence · combination 30 mg fatigue 71.4% weight decreased 71.4% anaemia 57.1% NCT02718066 · Phase 1/2 · registry result, not featured evidence · combination 30 mg fatigue 65.8% nausea 55.7% diarrhoea 53.2% NCT02718066 · Phase 1/2 · registry result, not featured evidence · combination 20 mg diarrhoea 66.7% dyspnoea 66.7% fatigue 66.7% NCT02718066 · Phase 1/2 · registry result, not featured evidence · combination 0.009 mg/kg q3w + 360 mg q3w pyrexia 100% rash 100% chills 66.7% NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination 0.006 mg/kg q3w + 240 mg q2w arthralgia 100% fatigue 100% headache 100% NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination 0.006 mg/kg q2w + 240 mg q2w chills 100% pyrexia 100% back pain 66.7% NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination 0.006 mg/kg q3w + 360 mg q3w fatigue 76% chills 64% cough 60% NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination 0.006 mg/kg q3w + 360 mg q3w fatigue 50.6% pyrexia 47.9% nausea 40.1% NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination 0.003 mg/kg q2w + 240 mg q2w chills 100% nasal congestion 100% arthralgia 66.7% NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination fatigue 90% diarrhoea 80% nausea 80% NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination diarrhoea 75% influenza like illness 75% pruritus 75% NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination decreased appetite 100% fatigue 100% influenza like illness 100% NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination fatigue 78.9% influenza like illness 68.4% nausea 57.9% NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination 400 mg abdominal discomfort 0% abdominal distension 0% abdominal hernia 0% NCT02658890 · Phase 1/2 · registry result, not featured evidence BMS-986205 400 mg + nivolumab 240 mg constipation 66.7% fatigue 66.7% vomiting 66.7% NCT02658890 · Phase 1/2 · registry result, not featured evidence · combination BMS-986205 200 mg + nivolumab 240 mg fatigue 66.7% nausea 44.4% vomiting 44.4% NCT02658890 · Phase 1/2 · registry result, not featured evidence · combination BMS-986205 200 mg decreased appetite 43.8% fatigue 43.8% nausea 43.8% NCT02658890 · Phase 1/2 · registry result, not featured evidence · combination BMS-986205 200 mg fatigue 52.9% alanine aminotransferase increased 35.3% urinary tract infection 35.3% NCT02658890 · Phase 1/2 · registry result, not featured evidence · combination BMS-986205 200 mg fatigue 42.9% constipation 28.6% nausea 28.6% NCT02658890 · Phase 1/2 · registry result, not featured evidence · combination BMS-986205 100 mg + nivolumab 240 mg fatigue 58.3% anaemia 50% decreased appetite 50% NCT02658890 · Phase 1/2 · registry result, not featured evidence · combination BMS-986205 100 mg asthenia 28.6% decreased appetite 28.6% nausea 28.6% NCT02658890 · Phase 1/2 · registry result, not featured evidence · combination BMS-986205 100 mg decreased appetite 55.6% nausea 50% vomiting 38.9% NCT02658890 · Phase 1/2 · registry result, not featured evidence · combination BMS-986205 100 mg decreased appetite 33.3% asthenia 26.7% constipation 26.7% NCT02658890 · Phase 1/2 · registry result, not featured evidence · combination 50 mg headache 100% oedema peripheral 100% vomiting 100% NCT02658890 · Phase 1/2 · registry result, not featured evidence BMS-986205 50 mg + nivolumab 240 mg fatigue 70% vomiting 60% decreased appetite 50% NCT02658890 · Phase 1/2 · registry result, not featured evidence · combination 50 mg abdominal discomfort 0% abdominal distension 0% abdominal hernia 0% NCT02658890 · Phase 1/2 · registry result, not featured evidence BMS-986205 25 mg + nivolumab 240 mg fatigue 57.1% nausea 57.1% vomiting 57.1% NCT02658890 · Phase 1/2 · registry result, not featured evidence · combination fatigue 64.3% nausea 42.9% diarrhoea 35.7% NCT02658890 · Phase 1/2 · registry result, not featured evidence constipation 29.4% fatigue 29.4% nausea 29.4% NCT02658890 · Phase 1/2 · registry result, not featured evidence · combination diarrhoea 50% fatigue 50% headache 50% NCT02658890 · Phase 1/2 · registry result, not featured evidence · combination 0.3 mg/kg + Nivolumab chills 100% nausea 100% pruritus 100% NCT03123783 · Phase 1/2 · registry result, not featured evidence · combination 0.1 mg/kg + Nivolumab anaemia 66.7% chills 66.7% decreased appetite 66.7% NCT03123783 · Phase 1/2 · registry result, not featured evidence · combination 0.03 mg/kg + Nivolumab fatigue 100% anxiety 33.3% arthralgia 33.3% NCT03123783 · Phase 1/2 · registry result, not featured evidence · combination chills 56.6% pyrexia 52.8% nausea 45.3% NCT03123783 · Phase 1/2 · registry result, not featured evidence · combination pyrexia 68.4% chills 50% nausea 47.4% NCT03123783 · Phase 1/2 · registry result, not featured evidence · combination nausea 50% pyrexia 50% dyspnoea 42.9% NCT03123783 · Phase 1/2 · registry result, not featured evidence · combination chills 46.4% asthenia 42.9% pyrexia 42.9% NCT03123783 · Phase 1/2 · registry result, not featured evidence · combination 3.2/4 mg anaemia 80% decreased appetite 80% fatigue 80% NCT02009449 · Phase 1 · registry result, not featured evidence 3.2/4 mg fatigue 100% anaemia 80% headache 60% NCT02009449 · Phase 1 · registry result, not featured evidence · combination 1.6/2 mg anaemia 75.2% fatigue 59% thrombocytopenia 59% NCT02009449 · Phase 1 · registry result, not featured evidence 1.6/2 mg fatigue 85.3% anaemia 76.5% thrombocytopenia 58.8% NCT02009449 · Phase 1 · registry result, not featured evidence · combination 1.6/2 mg anaemia 68.4% fatigue 59.6% cough 42.1% NCT02009449 · Phase 1 · registry result, not featured evidence · combination 0.8/1 mg anaemia 83.3% constipation 66.7% decreased appetite 66.7% NCT02009449 · Phase 1 · registry result, not featured evidence 0.8/1 mg fatigue 88.9% nausea 83.3% anaemia 77.8% NCT02009449 · Phase 1 · registry result, not featured evidence · combination 0.8/1 mg anaemia 83.3% thrombocytopenia 66.7% fatigue 50% NCT02009449 · Phase 1 · registry result, not featured evidence · combination 0.8/1 mg anaemia 83.3% fatigue 66.7% thrombocytopenia 66.7% NCT02009449 · Phase 1 · registry result, not featured evidence · combination 0.8/1 mg fatigue 100% decreased appetite 66.7% lipase increased 50% NCT02009449 · Phase 1 · registry result, not featured evidence · combination 0.8/1 mg fatigue 85.7% thrombocytopenia 71.4% anaemia 57.1% NCT02009449 · Phase 1 · registry result, not featured evidence · combination 0.8/1 mg activated partial thromboplastin time prolonged 100% alanine aminotransferase increased 100% anaemia 100% NCT02009449 · Phase 1 · registry result, not featured evidence · combination 0.8/1 mg anaemia 100% fatigue 100% thrombocytopenia 100% NCT02009449 · Phase 1 · registry result, not featured evidence · combination 0.4/0.5 mg anaemia 83.3% fatigue 83.3% nausea 83.3% NCT02009449 · Phase 1 · registry result, not featured evidence 0.4/0.5 mg anaemia 100% dyspnoea 66.7% fatigue 66.7% NCT02009449 · Phase 1 · registry result, not featured evidence · combination 0.4/0.5 mg thrombocytopenia 100% fatigue 66.7% anaemia 33.3% NCT02009449 · Phase 1 · registry result, not featured evidence · combination 0.4/0.5 mg fatigue 100% anaemia 80% hypokalaemia 60% NCT02009449 · Phase 1 · registry result, not featured evidence · combination 0.2/0.25 mg anaemia 50% fatigue 50% injection site erythema 50% NCT02009449 · Phase 1 · registry result, not featured evidence 0.2/0.25 mg asthenia 100% neutropenia 100% spermatic cord disorder 100% NCT02009449 · Phase 1 · registry result, not featured evidence · combination 0.08/0.1 mg injection site erythema 75% abdominal distension 50% abdominal pain 50% NCT02009449 · Phase 1 · registry result, not featured evidence 280 mg PO BID aspartate aminotransferase increased 14.3% cough 14.3% fatigue 14.3% NCT03229278 · Phase 1 · registry result, not featured evidence · combination 140 mg / 280 mg anemia 66.7% back pain 66.7% diarrhea 66.7% NCT03229278 · Phase 1 · registry result, not featured evidence · combination 140 mg PO BID lipase increased 66.7% alkaline phosphatase increased 33.3% anorexia 33.3% NCT03229278 · Phase 1 · registry result, not featured evidence · combination 140 mg PO daily hepatobiliary disorders - other, specify 100% abdominal pain 66.7% back pain 66.7% NCT03229278 · Phase 1 · registry result, not featured evidence · combination |
Colorectal Cancer
Shared mechanism: PD-1 · full Colorectal Cancer pipeline
Nivolumab
Marketed by Bristol-Myers Squibb and partners
NCT02060188 · Phase 2 · completed
The study was non-randomized, unblinded, and had no comparator arm; its 385 participants were distributed across multiple treatment cohorts, including small cohorts. The primary endpoint was investigator-assessed tumor response, and although results were posted, there was no controlled primary comparison to determine whether nivolumab improved outcomes.
Next expected readout: December 2026 · NCT04912765 (registry estimate)
No aligned efficacy figure on record for this race.
Opdivo Qvantig
Marketed by Bristol-Myers Squibb
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
No aligned efficacy figure on record for this race.
Results for Colorectal Cancer
There are not yet structured results for two selected drugs in this indication. Available results are listed below instead of an empty comparison table.
Nivolumab: registry results are on file for Colorectal Cancer, but their comparison mappings are not yet available.
Opdivo Qvantig: no structured comparison results are available for Colorectal Cancer.
Head and Neck Squamous Cell Carcinoma
Shared mechanism: PD-1 · full Head and Neck Squamous Cell Carcinoma pipeline
Nivolumab
Marketed by Bristol-Myers Squibb and partners
NCT02105636 · Phase 3 · completed
The trial randomly assigned 361 participants to open-label nivolumab or active comparator therapy, so treatment assignment was not blinded. Its objective primary endpoint, overall survival, was statistically significantly better with nivolumab, but the available record does not report a power calculation; these design limitations support a moderate grade rather than the highest grade.
Next expected readout: November 2026 · NCT02955290 (registry estimate)
Reported efficacy
Overall Survival (OS) (From date of randomization to date of death (Up to approximately 18 months)): Overall Survival (OS) (From date of randomization to date of death (Up to approximately 18 months)): Nivolumab 3mg/kg 7.49 Months (95% CI 5.49 to 9.1) | Investigators Choice 5.06 Months (95% CI 4.04 to 6.05) (met)
Result source: NCT02105636
Opdivo Qvantig
Marketed by Bristol-Myers Squibb
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
No aligned efficacy figure on record for this race.
Results for Head and Neck Squamous Cell Carcinoma
There are not yet structured results for two selected drugs in this indication. Available results are listed below instead of an empty comparison table.
Opdivo Qvantig: no structured comparison results are available for Head and Neck Squamous Cell Carcinoma.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Nivolumab
show 16 more results
show 7 more results
show 7 more results
show 6 more results
show 7 more results
Available safety results
Nivolumab
| Dropout rate | 0%280 mg PO BID NCT03229278 · Phase 1 · registry result, not featured evidence · combination show 11 more results0%140 mg / 280 mg NCT03229278 · Phase 1 · registry result, not featured evidence · combination 0%140 mg PO BID NCT03229278 · Phase 1 · registry result, not featured evidence · combination 0%140 mg PO daily NCT03229278 · Phase 1 · registry result, not featured evidence · combination 0%6 mg/kg + 3 mg/kg Q2W NCT02526017 · Phase 1 · registry result, not featured evidence · combination 0%6 mg/kg Q2W NCT02526017 · Phase 1 · registry result, not featured evidence —4 mg/kg + 3 mg/kg Q2W NCT02526017 · Phase 1 · registry result, not featured evidence · combination 0%4 mg/kg + 3 mg/kg Q3W NCT02526017 · Phase 1 · registry result, not featured evidence · combination 0%4 mg/kg Q2W NCT02526017 · Phase 1 · registry result, not featured evidence 25%2 mg/kg + 3 mg/kg Q2W NCT02526017 · Phase 1 · registry result, not featured evidence · combination 0%2 mg/kg Q2W NCT02526017 · Phase 1 · registry result, not featured evidence —1 mg/kg + 3 mg/kg Q2W NCT02526017 · Phase 1 · registry result, not featured evidence · combination |
|---|---|
| Discontinued due to AEs | —280 mg PO BID NCT03229278 · Phase 1 · registry result, not featured evidence · combination show 11 more results—140 mg / 280 mg NCT03229278 · Phase 1 · registry result, not featured evidence · combination —140 mg PO BID NCT03229278 · Phase 1 · registry result, not featured evidence · combination —140 mg PO daily NCT03229278 · Phase 1 · registry result, not featured evidence · combination —6 mg/kg + 3 mg/kg Q2W NCT02526017 · Phase 1 · registry result, not featured evidence · combination —6 mg/kg Q2W NCT02526017 · Phase 1 · registry result, not featured evidence —4 mg/kg + 3 mg/kg Q2W NCT02526017 · Phase 1 · registry result, not featured evidence · combination —4 mg/kg + 3 mg/kg Q3W NCT02526017 · Phase 1 · registry result, not featured evidence · combination —4 mg/kg Q2W NCT02526017 · Phase 1 · registry result, not featured evidence —2 mg/kg + 3 mg/kg Q2W NCT02526017 · Phase 1 · registry result, not featured evidence · combination —2 mg/kg Q2W NCT02526017 · Phase 1 · registry result, not featured evidence —1 mg/kg + 3 mg/kg Q2W NCT02526017 · Phase 1 · registry result, not featured evidence · combination |
| Serious AEs | 14.3%280 mg PO BID NCT03229278 · Phase 1 · registry result, not featured evidence · combination show 11 more results0%140 mg / 280 mg NCT03229278 · Phase 1 · registry result, not featured evidence · combination 66.7%140 mg PO BID NCT03229278 · Phase 1 · registry result, not featured evidence · combination 100%140 mg PO daily NCT03229278 · Phase 1 · registry result, not featured evidence · combination 50%6 mg/kg + 3 mg/kg Q2W NCT02526017 · Phase 1 · registry result, not featured evidence · combination 54.5%6 mg/kg Q2W NCT02526017 · Phase 1 · registry result, not featured evidence 52.1%4 mg/kg + 3 mg/kg Q2W NCT02526017 · Phase 1 · registry result, not featured evidence · combination 50%4 mg/kg + 3 mg/kg Q3W NCT02526017 · Phase 1 · registry result, not featured evidence · combination 10%4 mg/kg Q2W NCT02526017 · Phase 1 · registry result, not featured evidence 33.3%2 mg/kg + 3 mg/kg Q2W NCT02526017 · Phase 1 · registry result, not featured evidence · combination 33.3%2 mg/kg Q2W NCT02526017 · Phase 1 · registry result, not featured evidence 50%1 mg/kg + 3 mg/kg Q2W NCT02526017 · Phase 1 · registry result, not featured evidence · combination |
| Most frequent reported AEs | 280 mg PO BID aspartate aminotransferase increased 14.3% cough 14.3% fatigue 14.3% NCT03229278 · Phase 1 · registry result, not featured evidence · combination show 11 more results140 mg / 280 mg anemia 66.7% back pain 66.7% diarrhea 66.7% NCT03229278 · Phase 1 · registry result, not featured evidence · combination 140 mg PO BID lipase increased 66.7% alkaline phosphatase increased 33.3% anorexia 33.3% NCT03229278 · Phase 1 · registry result, not featured evidence · combination 140 mg PO daily hepatobiliary disorders - other, specify 100% abdominal pain 66.7% back pain 66.7% NCT03229278 · Phase 1 · registry result, not featured evidence · combination 6 mg/kg + 3 mg/kg Q2W fatigue 100% dehydration 83.3% periorbital oedema 83.3% NCT02526017 · Phase 1 · registry result, not featured evidence · combination 6 mg/kg Q2W aspartate aminotransferase increased 60% blood creatine phosphokinase increased 40% fatigue 40% NCT02526017 · Phase 1 · registry result, not featured evidence 4 mg/kg + 3 mg/kg Q2W fatigue 55.8% blood creatine phosphokinase increased 47.2% periorbital oedema 46% NCT02526017 · Phase 1 · registry result, not featured evidence · combination 4 mg/kg + 3 mg/kg Q3W candida infection 40% dizziness 40% fall 40% NCT02526017 · Phase 1 · registry result, not featured evidence · combination 4 mg/kg Q2W abdominal pain 45.5% aspartate aminotransferase increased 45.5% fatigue 45.5% NCT02526017 · Phase 1 · registry result, not featured evidence 2 mg/kg + 3 mg/kg Q2W amylase increased 33.3% arthralgia 33.3% aspartate aminotransferase increased 33.3% NCT02526017 · Phase 1 · registry result, not featured evidence · combination 2 mg/kg Q2W fatigue 66.7% blood alkaline phosphatase increased 33.3% blood bilirubin increased 33.3% NCT02526017 · Phase 1 · registry result, not featured evidence 1 mg/kg + 3 mg/kg Q2W anaemia 50% amylase increased 25% aspartate aminotransferase increased 25% NCT02526017 · Phase 1 · registry result, not featured evidence · combination |
Renal Cell Carcinoma
Shared mechanism: PD-1 · full Renal Cell Carcinoma pipeline
Nivolumab
Marketed by Bristol-Myers Squibb and partners
NCT02231749 · Phase 3 · completed
The trial was randomized and actively controlled, with 550 patients receiving nivolumab plus ipilimumab and 546 receiving sunitinib, but it was open-label. Its objective clinical endpoints were favorable for the nivolumab combination, with statistically significant comparisons reported for response rate, overall survival, and progression-free survival; however, the registry does not document the power calculation needed to establish adequate powering, so this is moderate evidence rather than strong evidence.
Next expected readout: December 2026 · NCT05263050 (registry estimate)
Reported efficacy
Overall Survival (OS) at Primary Endpoint (Randomization until 398 deaths, up to May 2015 (approximately 30 months)): Overall Survival (OS) at Primary Endpoint (Randomization until 398 deaths, up to May 2015 (approximately 30 months)): Nivolumab 25 months | Everolimus 19.55 months (95% CI 17.64 to 23.06) (met)
Result source: NCT01668784
Opdivo Qvantig
Marketed by Bristol-Myers Squibb
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
No aligned efficacy figure on record for this race.
Results for Renal Cell Carcinoma
There are not yet structured results for two selected drugs in this indication. Available results are listed below instead of an empty comparison table.
Opdivo Qvantig: registry results are on file for Renal Cell Carcinoma, but their comparison mappings are not yet available.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Nivolumab
show 2 more results
show 2 more results
show 9 more results
show 10 more results
show 21 more results
show 16 more results
show 7 more results
show 7 more results
Available safety results
Nivolumab
| Dropout rate | 100%40 mg NCT02718066 · Phase 1/2 · registry result, not featured evidence · combination show 47 more results100%30 mg NCT02718066 · Phase 1/2 · registry result, not featured evidence · combination 97.5%30 mg NCT02718066 · Phase 1/2 · registry result, not featured evidence · combination 100%20 mg NCT02718066 · Phase 1/2 · registry result, not featured evidence · combination 0%0.009 mg/kg q3w + 360 mg q3w NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination 0%0.006 mg/kg q3w + 240 mg q2w NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination 33.3%0.006 mg/kg q2w + 240 mg q2w NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination 20%0.006 mg/kg q3w + 360 mg q3w NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination 17.2%0.006 mg/kg q3w + 360 mg q3w NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination 0%0.003 mg/kg q2w + 240 mg q2w NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination 0%Part 3 Schedule Finding (Schedule NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination 0%Part 3 Schedule Finding (Schedule NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination 0%Part 3 Schedule Finding (Schedule NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination 10.5%Part 4 Dose Expansion of NKTR-214 NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination 100%3.2/4 mg NCT02009449 · Phase 1 · registry result, not featured evidence 100%3.2/4 mg NCT02009449 · Phase 1 · registry result, not featured evidence · combination 99.1%1.6/2 mg NCT02009449 · Phase 1 · registry result, not featured evidence 100%1.6/2 mg NCT02009449 · Phase 1 · registry result, not featured evidence · combination 96.5%1.6/2 mg NCT02009449 · Phase 1 · registry result, not featured evidence · combination 100%0.8/1 mg NCT02009449 · Phase 1 · registry result, not featured evidence 100%0.8/1 mg NCT02009449 · Phase 1 · registry result, not featured evidence · combination 100%0.8/1 mg NCT02009449 · Phase 1 · registry result, not featured evidence · combination 100%0.8/ 1 mg NCT02009449 · Phase 1 · registry result, not featured evidence · combination —0.8/1 mg NCT02009449 · Phase 1 · registry result, not featured evidence · combination 100%0.8/1 mg NCT02009449 · Phase 1 · registry result, not featured evidence · combination 85.7%0.8/1 mg NCT02009449 · Phase 1 · registry result, not featured evidence · combination 100%0.8/1 mg NCT02009449 · Phase 1 · registry result, not featured evidence · combination 100%0.8/1 mg NCT02009449 · Phase 1 · registry result, not featured evidence · combination 100%0.4/0.5 mg NCT02009449 · Phase 1 · registry result, not featured evidence 100%0.4/0.5 mg NCT02009449 · Phase 1 · registry result, not featured evidence · combination 100%0.4/ 0.5 mg NCT02009449 · Phase 1 · registry result, not featured evidence · combination —0.4/0.5 mg NCT02009449 · Phase 1 · registry result, not featured evidence · combination 100%0.4/0.5 mg NCT02009449 · Phase 1 · registry result, not featured evidence · combination 100%0.2/0.25 mg NCT02009449 · Phase 1 · registry result, not featured evidence 100%0.2/0.25 mg NCT02009449 · Phase 1 · registry result, not featured evidence · combination 100%0.08/0.1 mg NCT02009449 · Phase 1 · registry result, not featured evidence 0%280 mg PO BID NCT03229278 · Phase 1 · registry result, not featured evidence · combination 0%140 mg / 280 mg NCT03229278 · Phase 1 · registry result, not featured evidence · combination 0%140 mg PO BID NCT03229278 · Phase 1 · registry result, not featured evidence · combination 0%140 mg PO daily NCT03229278 · Phase 1 · registry result, not featured evidence · combination 0%6 mg/kg + 3 mg/kg Q2W NCT02526017 · Phase 1 · registry result, not featured evidence · combination 0%6 mg/kg Q2W NCT02526017 · Phase 1 · registry result, not featured evidence —4 mg/kg + 3 mg/kg Q2W NCT02526017 · Phase 1 · registry result, not featured evidence · combination 0%4 mg/kg + 3 mg/kg Q3W NCT02526017 · Phase 1 · registry result, not featured evidence · combination 0%4 mg/kg Q2W NCT02526017 · Phase 1 · registry result, not featured evidence 25%2 mg/kg + 3 mg/kg Q2W NCT02526017 · Phase 1 · registry result, not featured evidence · combination 0%2 mg/kg Q2W NCT02526017 · Phase 1 · registry result, not featured evidence —1 mg/kg + 3 mg/kg Q2W NCT02526017 · Phase 1 · registry result, not featured evidence · combination |
|---|---|
| Discontinued due to AEs | —40 mg NCT02718066 · Phase 1/2 · registry result, not featured evidence · combination show 47 more results—30 mg NCT02718066 · Phase 1/2 · registry result, not featured evidence · combination —30 mg NCT02718066 · Phase 1/2 · registry result, not featured evidence · combination —20 mg NCT02718066 · Phase 1/2 · registry result, not featured evidence · combination —0.009 mg/kg q3w + 360 mg q3w NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination —0.006 mg/kg q3w + 240 mg q2w NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination —0.006 mg/kg q2w + 240 mg q2w NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination —0.006 mg/kg q3w + 360 mg q3w NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination —0.006 mg/kg q3w + 360 mg q3w NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination —0.003 mg/kg q2w + 240 mg q2w NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination —Part 3 Schedule Finding (Schedule NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination —Part 3 Schedule Finding (Schedule NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination —Part 3 Schedule Finding (Schedule NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination —Part 4 Dose Expansion of NKTR-214 NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination —3.2/4 mg NCT02009449 · Phase 1 · registry result, not featured evidence —3.2/4 mg NCT02009449 · Phase 1 · registry result, not featured evidence · combination —1.6/2 mg NCT02009449 · Phase 1 · registry result, not featured evidence —1.6/2 mg NCT02009449 · Phase 1 · registry result, not featured evidence · combination —1.6/2 mg NCT02009449 · Phase 1 · registry result, not featured evidence · combination —0.8/1 mg NCT02009449 · Phase 1 · registry result, not featured evidence —0.8/1 mg NCT02009449 · Phase 1 · registry result, not featured evidence · combination —0.8/1 mg NCT02009449 · Phase 1 · registry result, not featured evidence · combination —0.8/ 1 mg NCT02009449 · Phase 1 · registry result, not featured evidence · combination —0.8/1 mg NCT02009449 · Phase 1 · registry result, not featured evidence · combination —0.8/1 mg NCT02009449 · Phase 1 · registry result, not featured evidence · combination —0.8/1 mg NCT02009449 · Phase 1 · registry result, not featured evidence · combination —0.8/1 mg NCT02009449 · Phase 1 · registry result, not featured evidence · combination —0.8/1 mg NCT02009449 · Phase 1 · registry result, not featured evidence · combination —0.4/0.5 mg NCT02009449 · Phase 1 · registry result, not featured evidence —0.4/0.5 mg NCT02009449 · Phase 1 · registry result, not featured evidence · combination —0.4/ 0.5 mg NCT02009449 · Phase 1 · registry result, not featured evidence · combination —0.4/0.5 mg NCT02009449 · Phase 1 · registry result, not featured evidence · combination —0.4/0.5 mg NCT02009449 · Phase 1 · registry result, not featured evidence · combination —0.2/0.25 mg NCT02009449 · Phase 1 · registry result, not featured evidence —0.2/0.25 mg NCT02009449 · Phase 1 · registry result, not featured evidence · combination —0.08/0.1 mg NCT02009449 · Phase 1 · registry result, not featured evidence —280 mg PO BID NCT03229278 · Phase 1 · registry result, not featured evidence · combination —140 mg / 280 mg NCT03229278 · Phase 1 · registry result, not featured evidence · combination —140 mg PO BID NCT03229278 · Phase 1 · registry result, not featured evidence · combination —140 mg PO daily NCT03229278 · Phase 1 · registry result, not featured evidence · combination —6 mg/kg + 3 mg/kg Q2W NCT02526017 · Phase 1 · registry result, not featured evidence · combination —6 mg/kg Q2W NCT02526017 · Phase 1 · registry result, not featured evidence —4 mg/kg + 3 mg/kg Q2W NCT02526017 · Phase 1 · registry result, not featured evidence · combination —4 mg/kg + 3 mg/kg Q3W NCT02526017 · Phase 1 · registry result, not featured evidence · combination —4 mg/kg Q2W NCT02526017 · Phase 1 · registry result, not featured evidence —2 mg/kg + 3 mg/kg Q2W NCT02526017 · Phase 1 · registry result, not featured evidence · combination —2 mg/kg Q2W NCT02526017 · Phase 1 · registry result, not featured evidence —1 mg/kg + 3 mg/kg Q2W NCT02526017 · Phase 1 · registry result, not featured evidence · combination |
| Serious AEs | 57.1%40 mg NCT02718066 · Phase 1/2 · registry result, not featured evidence · combination show 47 more results85.7%30 mg NCT02718066 · Phase 1/2 · registry result, not featured evidence · combination 49.4%30 mg NCT02718066 · Phase 1/2 · registry result, not featured evidence · combination 33.3%20 mg NCT02718066 · Phase 1/2 · registry result, not featured evidence · combination 66.7%0.009 mg/kg q3w + 360 mg q3w NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination 50%0.006 mg/kg q3w + 240 mg q2w NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination 0%0.006 mg/kg q2w + 240 mg q2w NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination 36%0.006 mg/kg q3w + 360 mg q3w NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination 44.7%0.006 mg/kg q3w + 360 mg q3w NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination 33.3%0.003 mg/kg q2w + 240 mg q2w NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination 60%Part 3 Schedule Finding (Schedule NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination 62.5%Part 3 Schedule Finding (Schedule NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination 33.3%Part 3 Schedule Finding (Schedule NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination 42.1%Part 4 Dose Expansion of NKTR-214 NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination 40%3.2/4 mg NCT02009449 · Phase 1 · registry result, not featured evidence 60%3.2/4 mg NCT02009449 · Phase 1 · registry result, not featured evidence · combination 51.3%1.6/2 mg NCT02009449 · Phase 1 · registry result, not featured evidence 47.1%1.6/2 mg NCT02009449 · Phase 1 · registry result, not featured evidence · combination 56.1%1.6/2 mg NCT02009449 · Phase 1 · registry result, not featured evidence · combination 33.3%0.8/1 mg NCT02009449 · Phase 1 · registry result, not featured evidence 55.6%0.8/1 mg NCT02009449 · Phase 1 · registry result, not featured evidence · combination 66.7%0.8/1 mg NCT02009449 · Phase 1 · registry result, not featured evidence · combination —0.8/ 1 mg NCT02009449 · Phase 1 · registry result, not featured evidence · combination 66.7%0.8/1 mg NCT02009449 · Phase 1 · registry result, not featured evidence · combination 16.7%0.8/1 mg NCT02009449 · Phase 1 · registry result, not featured evidence · combination 57.1%0.8/1 mg NCT02009449 · Phase 1 · registry result, not featured evidence · combination 100%0.8/1 mg NCT02009449 · Phase 1 · registry result, not featured evidence · combination 20%0.8/1 mg NCT02009449 · Phase 1 · registry result, not featured evidence · combination 33.3%0.4/0.5 mg NCT02009449 · Phase 1 · registry result, not featured evidence 33.3%0.4/0.5 mg NCT02009449 · Phase 1 · registry result, not featured evidence · combination —0.4/ 0.5 mg NCT02009449 · Phase 1 · registry result, not featured evidence · combination 33.3%0.4/0.5 mg NCT02009449 · Phase 1 · registry result, not featured evidence · combination 40%0.4/0.5 mg NCT02009449 · Phase 1 · registry result, not featured evidence · combination 33.3%0.2/0.25 mg NCT02009449 · Phase 1 · registry result, not featured evidence 0%0.2/0.25 mg NCT02009449 · Phase 1 · registry result, not featured evidence · combination 75%0.08/0.1 mg NCT02009449 · Phase 1 · registry result, not featured evidence 14.3%280 mg PO BID NCT03229278 · Phase 1 · registry result, not featured evidence · combination 0%140 mg / 280 mg NCT03229278 · Phase 1 · registry result, not featured evidence · combination 66.7%140 mg PO BID NCT03229278 · Phase 1 · registry result, not featured evidence · combination 100%140 mg PO daily NCT03229278 · Phase 1 · registry result, not featured evidence · combination 50%6 mg/kg + 3 mg/kg Q2W NCT02526017 · Phase 1 · registry result, not featured evidence · combination 54.5%6 mg/kg Q2W NCT02526017 · Phase 1 · registry result, not featured evidence 52.1%4 mg/kg + 3 mg/kg Q2W NCT02526017 · Phase 1 · registry result, not featured evidence · combination 50%4 mg/kg + 3 mg/kg Q3W NCT02526017 · Phase 1 · registry result, not featured evidence · combination 10%4 mg/kg Q2W NCT02526017 · Phase 1 · registry result, not featured evidence 33.3%2 mg/kg + 3 mg/kg Q2W NCT02526017 · Phase 1 · registry result, not featured evidence · combination 33.3%2 mg/kg Q2W NCT02526017 · Phase 1 · registry result, not featured evidence 50%1 mg/kg + 3 mg/kg Q2W NCT02526017 · Phase 1 · registry result, not featured evidence · combination |
| Most frequent reported AEs | 40 mg anaemia 57.1% decreased appetite 57.1% contusion 42.9% NCT02718066 · Phase 1/2 · registry result, not featured evidence · combination show 45 more results30 mg fatigue 71.4% weight decreased 71.4% anaemia 57.1% NCT02718066 · Phase 1/2 · registry result, not featured evidence · combination 30 mg fatigue 65.8% nausea 55.7% diarrhoea 53.2% NCT02718066 · Phase 1/2 · registry result, not featured evidence · combination 20 mg diarrhoea 66.7% dyspnoea 66.7% fatigue 66.7% NCT02718066 · Phase 1/2 · registry result, not featured evidence · combination 0.009 mg/kg q3w + 360 mg q3w pyrexia 100% rash 100% chills 66.7% NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination 0.006 mg/kg q3w + 240 mg q2w arthralgia 100% fatigue 100% headache 100% NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination 0.006 mg/kg q2w + 240 mg q2w chills 100% pyrexia 100% back pain 66.7% NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination 0.006 mg/kg q3w + 360 mg q3w fatigue 76% chills 64% cough 60% NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination 0.006 mg/kg q3w + 360 mg q3w fatigue 50.6% pyrexia 47.9% nausea 40.1% NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination 0.003 mg/kg q2w + 240 mg q2w chills 100% nasal congestion 100% arthralgia 66.7% NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination fatigue 90% diarrhoea 80% nausea 80% NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination diarrhoea 75% influenza like illness 75% pruritus 75% NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination decreased appetite 100% fatigue 100% influenza like illness 100% NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination fatigue 78.9% influenza like illness 68.4% nausea 57.9% NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination 3.2/4 mg anaemia 80% decreased appetite 80% fatigue 80% NCT02009449 · Phase 1 · registry result, not featured evidence 3.2/4 mg fatigue 100% anaemia 80% headache 60% NCT02009449 · Phase 1 · registry result, not featured evidence · combination 1.6/2 mg anaemia 75.2% fatigue 59% thrombocytopenia 59% NCT02009449 · Phase 1 · registry result, not featured evidence 1.6/2 mg fatigue 85.3% anaemia 76.5% thrombocytopenia 58.8% NCT02009449 · Phase 1 · registry result, not featured evidence · combination 1.6/2 mg anaemia 68.4% fatigue 59.6% cough 42.1% NCT02009449 · Phase 1 · registry result, not featured evidence · combination 0.8/1 mg anaemia 83.3% constipation 66.7% decreased appetite 66.7% NCT02009449 · Phase 1 · registry result, not featured evidence 0.8/1 mg fatigue 88.9% nausea 83.3% anaemia 77.8% NCT02009449 · Phase 1 · registry result, not featured evidence · combination 0.8/1 mg anaemia 83.3% thrombocytopenia 66.7% fatigue 50% NCT02009449 · Phase 1 · registry result, not featured evidence · combination 0.8/1 mg anaemia 83.3% fatigue 66.7% thrombocytopenia 66.7% NCT02009449 · Phase 1 · registry result, not featured evidence · combination 0.8/1 mg fatigue 100% decreased appetite 66.7% lipase increased 50% NCT02009449 · Phase 1 · registry result, not featured evidence · combination 0.8/1 mg fatigue 85.7% thrombocytopenia 71.4% anaemia 57.1% NCT02009449 · Phase 1 · registry result, not featured evidence · combination 0.8/1 mg activated partial thromboplastin time prolonged 100% alanine aminotransferase increased 100% anaemia 100% NCT02009449 · Phase 1 · registry result, not featured evidence · combination 0.8/1 mg anaemia 100% fatigue 100% thrombocytopenia 100% NCT02009449 · Phase 1 · registry result, not featured evidence · combination 0.4/0.5 mg anaemia 83.3% fatigue 83.3% nausea 83.3% NCT02009449 · Phase 1 · registry result, not featured evidence 0.4/0.5 mg anaemia 100% dyspnoea 66.7% fatigue 66.7% NCT02009449 · Phase 1 · registry result, not featured evidence · combination 0.4/0.5 mg thrombocytopenia 100% fatigue 66.7% anaemia 33.3% NCT02009449 · Phase 1 · registry result, not featured evidence · combination 0.4/0.5 mg fatigue 100% anaemia 80% hypokalaemia 60% NCT02009449 · Phase 1 · registry result, not featured evidence · combination 0.2/0.25 mg anaemia 50% fatigue 50% injection site erythema 50% NCT02009449 · Phase 1 · registry result, not featured evidence 0.2/0.25 mg asthenia 100% neutropenia 100% spermatic cord disorder 100% NCT02009449 · Phase 1 · registry result, not featured evidence · combination 0.08/0.1 mg injection site erythema 75% abdominal distension 50% abdominal pain 50% NCT02009449 · Phase 1 · registry result, not featured evidence 280 mg PO BID aspartate aminotransferase increased 14.3% cough 14.3% fatigue 14.3% NCT03229278 · Phase 1 · registry result, not featured evidence · combination 140 mg / 280 mg anemia 66.7% back pain 66.7% diarrhea 66.7% NCT03229278 · Phase 1 · registry result, not featured evidence · combination 140 mg PO BID lipase increased 66.7% alkaline phosphatase increased 33.3% anorexia 33.3% NCT03229278 · Phase 1 · registry result, not featured evidence · combination 140 mg PO daily hepatobiliary disorders - other, specify 100% abdominal pain 66.7% back pain 66.7% NCT03229278 · Phase 1 · registry result, not featured evidence · combination 6 mg/kg + 3 mg/kg Q2W fatigue 100% dehydration 83.3% periorbital oedema 83.3% NCT02526017 · Phase 1 · registry result, not featured evidence · combination 6 mg/kg Q2W aspartate aminotransferase increased 60% blood creatine phosphokinase increased 40% fatigue 40% NCT02526017 · Phase 1 · registry result, not featured evidence 4 mg/kg + 3 mg/kg Q2W fatigue 55.8% blood creatine phosphokinase increased 47.2% periorbital oedema 46% NCT02526017 · Phase 1 · registry result, not featured evidence · combination 4 mg/kg + 3 mg/kg Q3W candida infection 40% dizziness 40% fall 40% NCT02526017 · Phase 1 · registry result, not featured evidence · combination 4 mg/kg Q2W abdominal pain 45.5% aspartate aminotransferase increased 45.5% fatigue 45.5% NCT02526017 · Phase 1 · registry result, not featured evidence 2 mg/kg + 3 mg/kg Q2W amylase increased 33.3% arthralgia 33.3% aspartate aminotransferase increased 33.3% NCT02526017 · Phase 1 · registry result, not featured evidence · combination 2 mg/kg Q2W fatigue 66.7% blood alkaline phosphatase increased 33.3% blood bilirubin increased 33.3% NCT02526017 · Phase 1 · registry result, not featured evidence 1 mg/kg + 3 mg/kg Q2W anaemia 50% amylase increased 25% aspartate aminotransferase increased 25% NCT02526017 · Phase 1 · registry result, not featured evidence · combination |
Metastatic Colorectal Cancer
Shared mechanism: PD-1 · full Metastatic Colorectal Cancer pipeline
Nivolumab
Marketed by Bristol-Myers Squibb and partners
NCT02060188 · Phase 2 · completed
The study was non-randomized, unblinded, and had no comparator arm; its 385 participants were distributed across multiple treatment cohorts, including small cohorts. The primary endpoint was investigator-assessed tumor response, and although results were posted, there was no controlled primary comparison to determine whether nivolumab improved outcomes.
Next expected readout: December 2027 · NCT04017650 (registry estimate)
No aligned efficacy figure on record for this race.
Opdivo Qvantig
Marketed by Bristol-Myers Squibb
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
No aligned efficacy figure on record for this race.
Results for Metastatic Colorectal Cancer
There are not yet structured results for two selected drugs in this indication. Available results are listed below instead of an empty comparison table.
Nivolumab: registry results are on file for Metastatic Colorectal Cancer, but their comparison mappings are not yet available.
Opdivo Qvantig: no structured comparison results are available for Metastatic Colorectal Cancer.
Advanced Metastatic Colorectal Cancer
Shared mechanism: PD-1 · full Advanced Metastatic Colorectal Cancer pipeline
Nivolumab
Marketed by Bristol-Myers Squibb and partners
NCT02060188 · Phase 2 · completed
The study was non-randomized, unblinded, and had no comparator arm; its 385 participants were distributed across multiple treatment cohorts, including small cohorts. The primary endpoint was investigator-assessed tumor response, and although results were posted, there was no controlled primary comparison to determine whether nivolumab improved outcomes.
Next expected readout: December 2027 · NCT04017650 (registry estimate)
No aligned efficacy figure on record for this race.
Opdivo Qvantig
Marketed by Bristol-Myers Squibb
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
No aligned efficacy figure on record for this race.
Results for Advanced Metastatic Colorectal Cancer
There are not yet structured results for two selected drugs in this indication. Available results are listed below instead of an empty comparison table.
Nivolumab: registry results are on file for Advanced Metastatic Colorectal Cancer, but their comparison mappings are not yet available.
Opdivo Qvantig: no structured comparison results are available for Advanced Metastatic Colorectal Cancer.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Nivolumab's landscape · Opdivo Qvantig's landscape